Status:
UNKNOWN
The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer
Lead Sponsor:
Turku University Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
40-85 years
Phase:
NA
Brief Summary
Thirty-five men with newly diagnosed, metastatic prostate cancer are scanned with 18F-PSMA 1007 PET/CT at baseline, 3 weeks after the initiation of GnRH-antagonist, at one year and at the time of cast...
Detailed Description
In metastatic prostate cancer androgen deprivation therapy (ADT) has been traditionally used as a first line approach. Based on histological studies, animal models and PSMA-PET imaging, it is known th...
Eligibility Criteria
Inclusion
- Age: 40 to 85 years old
- Language spoken: Finnish
- Diagnosis: Histologically confirmed adenocarcinoma of prostate
- Adequate histological sampling consisting of at least 3 biopsy samples from each lobe
- No previous surgical, radiation or endocrine treatment for prostate carcinoma
- Clinical stage:T1c-T4NanyM1
- Serum creatinine ≤ 1,5 x ULN
- Mental status: Patients must be able to understand the meaning of the study
- Informed consent: The patient must sign the appropriate Ethical Committee approved informed consent documents in the presence of the designated staff
Exclusion
- Previous PC treatment
- Uncontrolled serious infection
- Prior usage of 5-ARI medication in past 12 months
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT03876912
Start Date
March 1 2019
End Date
March 1 2023
Last Update
April 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Turku University Hospital
Turku, Finland, 20500